Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
10.32
-0.19 (-1.81%)
At close: Jan 31, 2025, 4:00 PM
10.26
-0.06 (-0.56%)
After-hours: Jan 31, 2025, 7:56 PM EST
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $9.11M in the quarter ending September 30, 2024, a decrease of -24.02%. This brings the company's revenue in the last twelve months to $43.09M, down -16.77% year-over-year. In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, down -30.40%.
Revenue (ttm)
$43.09M
Revenue Growth
-16.77%
P/S Ratio
22.99
Revenue / Employee
$81,913
Employees
526
Market Cap
1.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
NTLA News
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 5 days ago - Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Shareholders to Connect - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Connect - Accesswire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Stockholders to Inquire about Securities Investigation - Accesswire
- 10 days ago - Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema - GlobeNewsWire
- 11 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation - Accesswire